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Objective: To investigate if exposure to exotoxins results in augmented serum cytokine response of patients with 
Staphylococcus aureus septicemia. 
Methods: Serum samples and strains from 63 patients with S. aureussepticemia were collected in a prospective study. 
Toxin production by strains in  vitro was determined by enzyme immunoassay (EIA) or reversed passive latex 
agglutination (RPLA). Antibodies against the toxins and cytokine levels in  serum on admission were analyzed with EIA. 
Results: Patients infected with strains producing staphylococcal enterotoxins (SEs) A, B, C and D and/or toxic shock 
syndrome toxin-1 (TSST-1) in vitro (n=37) showed higher serum TNF-a levels than those infected with non-toxigenic 
strains (p=0.04). A significant titer rise against the corresponding SE and/or TSST-1 produced by the isolate (14/35), 
indirectly reflecting exposure to  the antigen, was associated with higher TNF-a concentrations on admission than in  
those without titer rise (p=0.03). Patients with low antibody titers against SE and/or TSST-1 on admission (19/37) were 
found to  have higher serum TNF-a concentrations on admission than those with elevated antibody titers on admission 
(p=0.03). 
Conclusion: Patients infected with toxigenic S. aureus strains produce significantly higher levels of serum TNF-a on 
admission compared to  patients infected with non-toxigenic strains. 
Key words: bacteremia, interleukin-6, tumor necrosis factor, interleukin-I, interleukin-8, granulocyte colony-stimulating 
factor, antibody response, a-toxin, enterotoxin, toxic shock syndrome toxin-1. 
INTRODUCTION 
The pathogenesis of Gram-positive infections is not 
completely understood and no such ‘key factor’ as 
lipopolysaccharide (LPS)/endotoxin in Gram-negative 
infections has hitherto been demonstrated. However, 
various components of Gram-positive microorganisms, 
such as cell wall constituents and exotoxins of Stupkylo- 
coccus aureus, have been shown in vitro to trigger 
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different cascade systems and to induce production and 
release of cytokines [l]. Many of these cytokines are 
believed to be important mediators of immune and 
inflammatory responses and to play a central role in 
orchestrating the septic cascade [2]. 
S. uureus produces various exotoxins with the 
capacity to produce adverse effects on cell function and 
induce cell death. a-Toxin exerts hemolytic and cyto- 
toxic effects, is considered to be an important virulence 
factor and has substantial pathophysiologic effects [3]. 
a-Toxin has been shown in vitro to induce production 
and release of IL-lp by monocytes [4] and, to some 
extent, also tumor necrosis factor-a (TNF-a). Staphylo- 
coccal enterotoxins (SEs), as well as toxic shock 
syndrome toxin-1 (TSST- l) ,  elicit a sepsis-like status 
with fever, multiple organ dysfunction, shock, and even 
death following parenteral administration [5]. SEs and 
TSST-1 are recognized as superantigens [6] and in vitro 
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as potent inducers of cytokine production [5,7,8]. 
Consequently, there are reasons to believe that staphylo- 
coccal exotoxins have important systemic effects and 
thereby contribute to the pathogenesis of septicemia 
and shock syndromes. 
In previous studies in patients with S. aureus 
septicemia we have shown that (1) a high prevalence 
of toxigenic strains are isolated from blood [9,10], (2) 
a majority of patients develop a positive antibody 
response against exotoxins [9,10], and (3) a high 
proportion of patients show elevated serum levels of 
the cytokines TNF-a, interleukin-6 (IL-6), IL-8 and 
granulocyte colony-stimulating factor (G-CSF) on 
admission [ 1 1,121. 
The aim of the present study was to investigate if 
exposure to exotoxins results in augmented serum 
cytolune response of patients with S. aureus septicemia. 
MATERIALS AND METHODS 
Patients 
In a prospective study, 63 consecutive patients with 
verified (Bactec 660 HP) S. aureus septicemia admitted 
to the Department of Infectious Diseases of the Orebro 
Medical Center Hospital during 1988-1 992 were 
further studied. Patient sera were collected as early as 
possible when S. aureus septicemia was suspected or 
verified. Samples were again collected at least 3 and 7 
days later and then once weekly. Sera were stored at 
- 7OoC pending analysis. 
Two or more positive blood cultures were found in 
58 patients, but from five patients one positive blood 
culture was obtained. O n  admission these patients 
displayed clinical signs of septicemia, such as fever 
>38SoC, shaking chills, tachypnea, tachycardia, hypo- 
tension, leukocytosis, and/or elevated CRF! 
The median age of the study population was 
71 years (range 10-91 years) and 59% were men. 
Immunosuppressive treatment was present in eight 
patients and malignant diseases in three additional 
patients. Fourteen patients had diabetes mellitus and 
two had non-diabetic renal insufficiency. Forty-nine 
patients had community-acquired septicemia, and in 14 
cases the septicemia was contracted during a hospital 
stay. Two patients were known intravenous drug 
addicts. None of the included patients had an HIV 
infection. 
The mean delay (i.e. number ofdays from the onset 
of the disease to admission) was 5.2 days (median 3 
days, range 0-45 days) and 18 patients had a delay of 
more than 1 week. 
Complicated septicemia, such as acute osteomyelitis, 
septic arthritis or extensive abscesses, was found in 43 
patients. Fifteen patients (24%) fulfilled the criteria 
of endocarditis (one definite, six probable and eight 
possible) according to the strict case definitions pro- 
posed by von Reyn et a1 [13]. Seven patients fulfilled 
the Duke criteria of definite infective endocarditis [14]. 
Five patients (8%) died in close relation to the acute 
septicemic event (3-15 days after admission to hospital). 
Controls 
Serum samples from blood donors (n=20) were used as 
normal controls for cytokine concentrations. 
Production of a-toxin, enterotoxins A, B, C and D and 
TSST-1 by isolated S. aureus strains in vitro 
The S. aureus strains were subcultured on blood agar 
plates overnight and then suspended in brain heart 
infusion (BHI) broth and incubated in flasks on a 
shaker at 37°C overnight. The production of a-toxin 
in the resulting supernatant was detected and quan- 
titated by a previously described monoclonal-based 
enzyme immunoassay (EIA) [9]. A correlation ( ~ 0 . 8 1 ,  
p=O.OOOl) between a-toxin concentration (mg/L) as 
quantitated by EIA and the hemolytic activity [15] was 
found. 
The production of SEs A-D and TSST-1 was 
tested by reversed passive latex agglutination (RPLA), 
using the commercial kits SET-RPLA and TST-RPLA 
(Oxoid, Unipath Ltd, Hampshire, England) according 
to the manufacturer’s instructions. 
Demonstration of antibodies against a-toxin, enterotoxins 
A, B, C and D and TSST-1 
The EIA procedures for determination of antibodies 
against a-toxin, SEA, SEB, SEC and SED and TSST- 
1 were carried out as described previously [9,10]. 
The relative EIA titer was defined as the 
absorbance value multiplied by the serum dilution 
factor (1000). The cut-off level was established in a 
blood-donor population as corresponding to the 95th 
percentile and set at a titer of 550 for anti-a-toxin, 380 
for anti-SEA and anti-SED, 1100 for anti-SEB, 2600 
for anti-SEC and 1300 for anti-TSST-1. A positive 
antibody response was defined as a high titer (above the 
cut-off level) on admission or a titer rise (22-fold 
increase in EIA titer between two serum samples when 
followed up for 2 1 0  days; significant titer rise, or an 
increase above cut-off). 
TNF-a, IL-lp, 11-6.11-8 and G-CSF assays 
The cytokine analyses were performed by commercial 
EIAs for TNF-a, IL-lp, IL-6 and IL-8 EASIAs 
(enzyme amplified sensitivity immunoassays), from 
Medgenix Diagnostics, Fleurus, Belgium and by 
Quantikine Human G-CSF Immunoassay from R&D 
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Systems, Minneapolis, MN. The assays were performed 
according to the manufacturers’ instructions. 
Statistical analysis 
The Mann-Whitney U test was used for comparing 
various parameters in different groups, and Spearman’s 
rank correlation test was applied for evaluating cor- 
relations between parameters. A p value of <0.05 was 
considered significant. 
The statistical package StatView 4.01 was used for 
the calculations. 
The production of exotoxins by the isolated S. aureus 
strains in vitro and the antibody response against these 
toxins in vivo are summarized in Table 1. 
Production of a-toxin was demonstrated in all 
isolated strains of S. aureus from the 63 septicemic 
patients. The amounts released by the strains in vitro 
were quantitated and ranged from 2.5 to 150 mg/L. 
A majority (59%) of the strains were also found to 
produce SEs and/or TSST-1. Overall positive antibody 
responses against a-toxin and SEs and/or TSST-1 were 
found in 64% and 84% of the patients, respectively. Of  
patients infected with a toxin-producing strain (SEA, 
SEB, SEC and SED or TSST-I), a positive antibody 
response against the corresponding toxin developed in 
79-92%. More than one third of the patients showed a 
significant titer rise against the toxin when followed up 
for 2 1 0  days from the onset of illness and about the 
same proportion also displayed elevated antibody titers 
against the different toxins at the time of admission. 
The serum concentrations of the cytolunes TNF- 
a, IL-6, IL-8 and G-CSF on admission in 63 patients 
with S. attreur septicemia are shown in Figure 1. The 
medlan cytokine concentrations (and the range) were 
found to be 38 (0-276) pg/mL for TNF-a, 245 
(0 to > 1000) pg/mL for IL-6, 94 (8-5400) pg/mL for 
G-CSF, and 31 (2-1366) pg/mL for IL-8. Twenty 
patients with a short delay (median 1 day) were analyzed 
for IL-1P and the median level (and the range) for 
IL-lP was < 2  (<2-115) pg/mL. 
Non-survivors had higher serum TNF-cx con- 
centrations on admission (median value 105 pg/mL) 
than survivors (median value 35 pg/mL) but the 
difference was not statistically significant (p=0.07). 
Non-survivors, however, died at different phases of the 
clinical course. One patient, with endocarditis of the 
mitral valve, died within 3 days of multiple organ failure 
and disseminated intravascular coagulation (DIC), and 
a second patient died on day 10 because of an extensive 
renal abscess containing S. uureus and recurrent septi- 
cemia. The three additional patients died during 
later phases of the disease, one from acute myocardial 
infarction on day 14 and two from progressive renal 
failure on days 14 and 15 after admission to hospital. 
Two of these patients were infected with non-toxigenic 
S. aweus strains and showed no antibody response 
against SEs. From the three remaining patients, strains 
producing SEA, SEC, and both SEA and SED, 
respectively, were isolated. In two patients significant 
antibody titer rises were found, but the last patient 
already showed elevated antibody titers (above cut-ofI) 
against both SEA and SED on admission. 
Patients with immunosuppression (n=8)  showed 
slightly higher median serum TNF-a levels (49 pg/mL 
and 35 pg/mL, respectively) than those without 
immunosuppression. 
Septicemic patients infected with S. aureus strains 
producing SEA, SEB, SEC and SED and/or TSST-1 
(n=37) displayed higher serum TNF-a levels on 
admission than those infected with non-toxin- 
producing (n=26) strains (p=0.04) (Figure 2). 
An overall positive antibody response was not 
associated with higher serum cytokine levels compared 
to a negative antibody response, but patients infected 
with a toxigenic strain and with a significant rise in titer 
Table 1 Production of staphylococcal exotoxins by strains and the corresponding antibody response against these toxins in 
patients with S. a m u s  septicemia 
Poyitive antibody Significant High titers 
Strains response” titer rise“ on admission 
a- Toxin 63/63 (100%) 36/57 (63%) 19/57 (33%) 23/63 (3%) 
SEs A, €3, C and D 37/63 (59%) 48/57 (84%) 
and or TSST-I 
Patients infected 32/35 (91%) 
with SE and/or 
TSST-1 toxigenic strains 
24/57 (42%) 
14/35 (40%) 
26/63 (41%)) 
19/37 (51%) 
^Patients followed up for <10 days not included. 
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Figure 1 Serum cytokine concentrations on admission in patients with S. aureus septicemia infected with toxigenic (0) or 
non-toxigenic (0) strains. 
Table 2 The distribution of the serum median (and range) TNF-a, IL-6, 1L-8 and G-CSF concentrations ( p g / d )  in 
patients with S. atlieus septicemia 
Production of SEA, SEB, SEC and 
SED and/or TSST-1 by 
isolated strains 
Antibody response in 
patients infected with 
toxigenic strains 
~~~ ~ ~~ 
Tomgenic Non- toxigenic 
Corlmls strain strain 
No. 20 37 26 
IL-6 <3 216 (‘3 to >1000) 232 (<3  to >1000) 
TNF-a 14 (9-20) 49 (<3-276) 24 (<3-230) 
IL-8 9 (4-87) 35 (2-1366) 12 (2-1271) 
G-CSF 32 (14-85) 92 (10-3100) 95 (8-5400) 
Antibody Antibody 
rise positive rise neganve 
14 21 
74 (<3-365) 22 (<3-155) 
175 (26-3100) 55 (10-680) 
398 (81 to >iooo) 197 (<3 to >loon) 
53 (2-1366j 18 (3-1282) 
Antibody titers on 
admission in patienn infected 
with toxigenic strains 
Low High 
antibody titer antibody titer 
19 18 
273 (81 to >iooo) 197 (<3 to >loon) 
72 (<3-365) 22 (<3-155) 
47 (2-889) 19 (3-1366) 
148 (26-3100) 54 (10480) 
370 
-r 
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Figure 2 Serum TNF-a levels (median values: boxes, 23th to 75th percentile; vertical bars, 10th to 90th percentile) in 
patients with S. aureus septicemia related to in vitro production by strains, development of significant titer rise, and antibody 
titers on admission against SEs A-D and/or TSST-1. 
against the corresponding SE and/or TSST-1 produced 
by the strain (14/35) were found to have higher 
TNF-a concentrations on admission (p=0.03) than 
those without a significant titer rise (21/35). 
Furthermore, patients with low antibody titers 
(below the cut-off defined for the respective toxin) 
against SEs A-D and/or TSST-1 at the time of 
admission (1 9/37) showed significantly higher serum 
TNF-a concentrations on admission than those with 
elevated antibody titers at the time of admission 
( p  = 0.03). 
No statistically significant differences were found 
concerning IL-6, IL-8 or G-CSF, but a tendency to the 
same result as for TNF-a was seen in the three different 
groups for these cytokines (Table 2). 
No correlations were found between a-toxin 
production by the strains in vitro and the serum cyto- 
kine (TNF-a, IL-6, IL-8 or G-CSF) levels on 
admission, and neither were there any differences in 
cytokine concentrations in the two groups regarding 
antibody response and antibody admission levels. 
DISCUSSION 
SEs and TSST-1 are potent inducers of cytokine 
production in blood mononuclear cells in vitro [7,8], 
and the SEs have been found to display superantigenic 
properties [6]. However, the significance of these 
effects in vivo, in acute septic disorders, has not been 
completely determined, although associations between 
superantigens and shock syndromes have been pro- 
posed [16]. 
In vitro, a majority of the S. aweus strains isolated 
froni our patients with septicemia &d produce SEs A-D 
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and/or TSST-I, and the percentages of toxigenic strains 
were in accordance with previous reports [17,18]. 
The detection of SEs or TSST-1 directly in serum 
samples from patients with ongoing infections has 
hitherto not been accomplished [19]. Toxins might 
rapidly be cleared from serum due to a high prevalence 
of circulating antibodies or by other mechanisms 
exerted by the innate and adaptive immune defense 
systems. The sensitivity of the applied test methods may 
also have been insufficient. 
However, the development of antibodies against 
enterotoxins may be regarded as indirect evidence of 
toxin production in vivo. In our study [lo] and in 
a previous report [17], a majority of patients with 
S. aureus septicemia have been found to develop a 
positive antibody response to the corresponding toxin 
produced by the isolated strain. We have also shown 
that patients with a positive antibody response against 
a-toxin were infected with S. aureus strains producing 
statistically significantly higher quantities of a-toxin in 
vitro than the strains infecting those with a negative 
antibody response [20]. 
The possible relationship between the exposure of 
the immune system to SEs, determined as in vitro 
production of toxins by the isolated strains as well as the 
antibody response in vivo, and the cytokine response in 
vivo in patients with ongoing S. aureus septicemia was 
analyzed. 
Patients infected with strains producing SEs in vitro 
were found to have significantly higher serum TNF-a 
concentrations on admission than those infected with 
non-toxigenic strains. Whether the toxin is actually 
expressed in vivo has not yet been confirmed, but 
animal experiments have indicated that there is no 
significant difference between in vitro and in vivo 
production [Zl]. 
Patients with a significant rise in antibody titer, 
indicating a current exposure to the corresponding 
antigen (SEA, SEB, SEC and SED and/or TSST-l), 
were also found to have higher serum TNF-a levels on 
admission compared to those without titer rise, further 
indicating a relation between exposure to toxins and 
TNF-a production. 
Patients with high titers of pre-existing antibodies 
against the toxins probably have the abihty to neutralize 
the toxin, whereas those with low antibody titers may 
be more extensively exposed to the toxins. In addition, 
patients with low antibody titers against SEs and/or 
TSST-1 on admission had significantly higher serum 
TNF-a levels than those with antibody titers above the 
cut-off. The same tendency as for TNF-a was also seen 
with IL-6, IL-8 and G-CSF, but not at statistically 
significant levels (Table 2) .  This finding may indicate 
an immune-modulating effect of these antibodies, 
observed as a less extensive cytokine response in those 
with elevated andbody titers compared to those with 
low antibody titers on admission. 
There are quantitative and temporal differences 
concerning the cytokines produced and released in 
vitro after stimulation of mononuclear blood cells with 
various toxins such as SEA and LPS [7].  The cytokines 
produced in vitro after stimulation with SEA include 
IL-la, IL-P, TNF-P, TNF-a, and IL-8, but to a 
considerably lesser extent IL-6 [7]. This may partly 
explain the observed relationship between serum TNF- 
a levels and a conceivable exposure to the SEs in the 
present study. The same tendency was also observed 
regarding IL-6, IL-8 and G-CSF, but further studies are 
required to confirm this. To our knowledge, there is no 
report on the production and release of G-CSF from 
immunocompetent cells after challenge with SEs or 
TSST-1. Only two out of 20 patients with a short 
admission delay showed elevated serum IL-1p con- 
centrations. This may be explained by the fact that IL- 
1 is released early in the acute phase of infection and is 
rapidly downregulated by counteracting cytokines and 
by soluble receptors and receptor antagonists. IL-1 also 
primarily remains cell-associated and mediates its action 
through the membrane-bound form [22]. 
In conclusion, these findings indicate that the 
host immune system is exposed to SEs during ongoing 
S. aureus septicemia, thereby inducing production 
and release of various cytokines, especially TNF-a, 
that mediate important pathogenetic processes and 
contribute to the development of the systemic inflam- 
matory response. Serum antibodies against these toxins 
seem to have a modulating role in the cytokine response. 
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